SOUTH SAN FRANCISCO, Calif. and WHITEHOUSE STATION, N.J. -- Sunesis Pharmaceuticals, Inc. and Merck & Co., Inc. today announced that they have entered into a multi-year research collaboration to discover novel oral drugs for the treatment of viral infections.
Sunesis will provide Merck with a series of small molecule compounds targeting viral infections. These compounds were derived from Tethering(SM), Sunesis proprietary fragment-based drug discovery platform. Merck will be responsible for advancing these compounds into lead optimization, preclinical development, and clinical studies. Merck will pay annual license fees for ongoing access to Sunesis core technology as a means of identifying additional compounds for the treatment of viral infections.
Under the terms of the agreement, Sunesis will receive an upfront payment, annual license fees and payments based on the achievement of development milestones. In addition, Sunesis will receive royalty payments based on net sales for products resulting from the collaboration. Merck receives an exclusive worldwide license to any products resulting from the collaboration.
This is the second collaboration between the two companies. A previous collaboration to discover new small molecule medicines for Alzheimers disease was signed in February 2003.
Sunesis is a valued partner to Merck, and we are pleased to be collaborating with them on a second program, said Merv Turner, Ph.D., senior vice president of worldwide licensing and external research at Merck. Viral infections are an important area of research for Merck, and we believe that Sunesis fragment-based drug discovery approach has the potential to play a key role in the discovery of potent and targeted anti-viral medicines.
Merck is dedicated to quality and innovation in medicine, and we are proud to be collaborating with them on another important therapeutic program, said Daniel Swisher, CEO of Sunesis Pharmaceuticals. The continued satisfaction of our partners further validates the capacity of Sunesis drug discovery engine to consistently produce highly targeted small molecule medicines.
Sunesis will apply the companys proprietary Tethering(SM) approach to identify fragments that bind with high affinity to antiviral targets. Sunesis will leverage these fragments as the foundation for potential new drugs with the ability to address viral infections.
Source: Sunesis Pharmaceuticals
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
2 Commerce Drive
Cranbury, NJ 08512